Qiagen Biotechnology Malaysia Sdn Bhd has installed the company’s first GeneReader Next-Generation Sequencing (NGS) System in Malaysia. The installation of the GeneReader NGS System at Pathomics Health Sdn Bhd, a digital health care solution company in Kuala Lumpur, enables actionable insights to support research that will benefit the country’s cancer research community.
This also has positive implications for patient care as scientist would be able to document a wider range of genetic mutations and investigate further the genetic basis of cancer cells within the human body.
“Pathomics Health is excited to be the lab with Malaysia’s first GeneReader NGS System,” said Dr. Ron Tan, a scientific advisor to Pathomics Health.
“The GeneReader NGS simplifies the NGS workflow and generates an interpreted result without hassle. We know that NGS technology has achieved outstanding success, posting breakthroughs in the life sciences, applied testing, pharma and molecular diagnostics. We are particularly pleased to offer GeneReader system’s ability to explore a tumour’s molecular nature more quickly and affordably than other platforms.”
The GeneReader NGS System was installed at Pathomics Health to enable the company to provide sequencing services. The collaboration also aims to develop new integrative tools for use in cancer diagnosis and prognosis.
Pathomics Health and the University of Malaya intend to share and improve the application, understanding and available resources associated with molecular pathology, particularly its application to cancer, through their respective networks in academia and industry.
Qiagen is the world’s leading provider of the first complete “Sample to Insight” next-generation sequencing solution. Its GeneReader NGS is simpler and more cost-effective for laboratories.
One in four Malaysians will develop cancer by age 75 and roughly 100,000 Malaysians suffer from cancer each year, according to Deputy Health Minister Datuk Seri Dr Hilmi Yahaya. By the year 2020, the incidence of cancer in Malaysia is expected to increase by 15%.